RxSight (RXST) EBIAT (2020 - 2025)
RxSight (RXST) has disclosed EBIAT for 6 consecutive years, with -$9.2 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, EBIAT fell 54.13% year-over-year to -$9.2 million, compared with a TTM value of -$38.9 million through Dec 2025, down 41.85%, and an annual FY2025 reading of -$38.9 million, down 41.85% over the prior year.
- EBIAT was -$9.2 million for Q4 2025 at RxSight, up from -$9.8 million in the prior quarter.
- Across five years, EBIAT topped out at -$5.9 million in Q4 2024 and bottomed at -$17.6 million in Q1 2022.
- Average EBIAT over 5 years is -$11.5 million, with a median of -$12.1 million recorded in 2023.
- The sharpest move saw EBIAT tumbled 159.83% in 2021, then soared 55.96% in 2024.
- Year by year, EBIAT stood at -$15.7 million in 2021, then rose by 0.78% to -$15.6 million in 2022, then skyrocketed by 41.21% to -$9.2 million in 2023, then soared by 35.29% to -$5.9 million in 2024, then tumbled by 54.13% to -$9.2 million in 2025.
- Business Quant data shows EBIAT for RXST at -$9.2 million in Q4 2025, -$9.8 million in Q3 2025, and -$11.8 million in Q2 2025.